发布求助
文献互助 智能选刊 最新文献

Annual review of pharmacology and toxicology最新文献

筛选
英文 中文
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. SARS-CoV-2感染的实验模型:研究COVID-19发病机制和潜在治疗的可能平台
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-02-19 DOI: 10.1146/annurev-pharmtox-121120-012309
Sareh Pandamooz, Benjamin Jurek, Carl-Philipp Meinung, Zahra Baharvand, Alireza Sahebi Shahem-Abadi, Silke Haerteis, Jaleel A Miyan, James Downing, Mehdi Dianatpour, Afshin Borhani-Haghighi, Mohammad Saied Salehi
{"title":"Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments.","authors":"Sareh Pandamooz,&nbsp;Benjamin Jurek,&nbsp;Carl-Philipp Meinung,&nbsp;Zahra Baharvand,&nbsp;Alireza Sahebi Shahem-Abadi,&nbsp;Silke Haerteis,&nbsp;Jaleel A Miyan,&nbsp;James Downing,&nbsp;Mehdi Dianatpour,&nbsp;Afshin Borhani-Haghighi,&nbsp;Mohammad Saied Salehi","doi":"10.1146/annurev-pharmtox-121120-012309","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-121120-012309","url":null,"abstract":"<p><p>In December 2019, a novel coronavirus crossed species barriers to infect humans and was effectively transmitted from person to person, leading to a worldwide pandemic. Development of effective clinical interventions, including vaccines and antiviral drugs that could prevent or limit theburden or transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health priority. It is thus of utmost importance to assess possible therapeutic strategies against SARS-CoV-2 using experimental models that recapitulate aspects of the human disease. Here, we review available models currently being developed and used to study SARS-CoV-2 infection and highlight their application to screen potential therapeutic approaches, including repurposed antiviral drugs and vaccines. Each identified model provides a valuable insight into SARS-CoV-2 cellular tropism, replication kinetics, and cell damage that could ultimately enhance understanding of SARS-CoV-2 pathogenesis and protective immunity.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25385017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Systems Biology of the Vasopressin V2 Receptor: New Tools for Discovery of Molecular Actions of a GPCR. 血管加压素V2受体的系统生物学:发现GPCR分子作用的新工具。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-27 DOI: 10.1146/annurev-pharmtox-052120-011012
Lihe Chen, Hyun Jun Jung, Arnab Datta, Euijung Park, Brian G Poll, Hiroaki Kikuchi, Kirby T Leo, Yash Mehta, Spencer Lewis, Syed J Khundmiri, Shaza Khan, Chung-Lin Chou, Viswanathan Raghuram, Chin-Rang Yang, Mark A Knepper
{"title":"Systems Biology of the Vasopressin V2 Receptor: New Tools for Discovery of Molecular Actions of a GPCR.","authors":"Lihe Chen, Hyun Jun Jung, Arnab Datta, Euijung Park, Brian G Poll, Hiroaki Kikuchi, Kirby T Leo, Yash Mehta, Spencer Lewis, Syed J Khundmiri, Shaza Khan, Chung-Lin Chou, Viswanathan Raghuram, Chin-Rang Yang, Mark A Knepper","doi":"10.1146/annurev-pharmtox-052120-011012","DOIUrl":"10.1146/annurev-pharmtox-052120-011012","url":null,"abstract":"<p><p>Systems biology can be defined as the study of a biological process in which all of the relevant components are investigated together in parallel to discover the mechanism. Although the approach is not new, it has come to the forefront as a result of genome sequencing projects completed in the first few years of the current century. It has elements of large-scale data acquisition (chiefly next-generation sequencing-based methods and protein mass spectrometry) and large-scale data analysis (big data integration and Bayesian modeling). Here we discuss these methodologies and show how they can be applied to understand the downstream effects of GPCR signaling, specifically looking at how the neurohypophyseal peptide hormone vasopressin, working through the V2 receptor and PKA activation, regulates the water channel aquaporin-2. The emerging picture provides a detailedframework for understanding the molecular mechanisms involved in water balance disorders, pointing the way to improved treatment of both polyuric disorders and water-retention disorders causing dilutional hyponatremia.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39464828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic Retinoids Beyond Cancer Therapy. 合成类维生素a超越癌症治疗。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 DOI: 10.1146/annurev-pharmtox-052120-104428
Lorraine J Gudas
{"title":"Synthetic Retinoids Beyond Cancer Therapy.","authors":"Lorraine J Gudas","doi":"10.1146/annurev-pharmtox-052120-104428","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052120-104428","url":null,"abstract":"<p><p>While the uses of retinoids for cancer treatment continue to evolve, this review focuses on other therapeutic areas in which retinoids [retinol (vitamin A), all-<i>trans</i> retinoic acid (RA), and synthetic retinoic acid receptor (RAR)α-, β-, and γ-selective agonists] are being used and on promising new research that suggests additional uses for retinoids for the treatment of disorders of the kidneys, skeletal muscles, heart, pancreas, liver, nervous system, skin, and other organs. The most mature area, in terms of US Food and Drug Administration-approved, RAR-selective agonists, is for treatment of various skin diseases. Synthetic retinoid agonists have major advantages over endogenous RAR agonists such as RA. Because they act through a specific RAR, side effects may be minimized, and synthetic retinoids often have better pharmaceutical properties than does RA. Based on our increasing knowledge of the multiple roles of retinoids in development, epigenetic regulation, and tissue repair, other exciting therapeutic areas are emerging.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264058/pdf/nihms-1904578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9978007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders. 唐氏综合症的产前和产后药物治疗:预防或改善神经发育和神经退行性疾病的研究。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 DOI: 10.1146/annurev-pharmtox-041521-103641
Renata Bartesaghi, Stefano Vicari, William C Mobley
{"title":"Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders.","authors":"Renata Bartesaghi,&nbsp;Stefano Vicari,&nbsp;William C Mobley","doi":"10.1146/annurev-pharmtox-041521-103641","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-041521-103641","url":null,"abstract":"<p><p>Those with Down syndrome (DS)-trisomy for chromosome 21-are routinely impacted by cognitive dysfunction and behavioral challenges in children and adults and Alzheimer's disease in older adults. No proven treatments specifically address these cognitive or behavioral changes. However, advances in the establishment of rodent models and human cell models promise to support development of such treatments. A research agenda that emphasizes the identification of overexpressed genes that contribute demonstrably to abnormalities in cognition and behavior in model systems constitutes a rational next step. Normalizing expression of such genes may usher in an era of successful treatments applicable across the life span for those with DS.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632639/pdf/nihms-1845638.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10841686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. 脆性X染色体综合征:经验教训和新的治疗途径即将出现。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-09 DOI: 10.1146/annurev-pharmtox-052120-090147
Randi J Hagerman, Paul J Hagerman
{"title":"Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon.","authors":"Randi J Hagerman,&nbsp;Paul J Hagerman","doi":"10.1146/annurev-pharmtox-052120-090147","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052120-090147","url":null,"abstract":"<p><p>Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading single-gene form of autism spectrum disorder, encompassing cognitive, behavioral, and physical forms of clinical involvement. FXS is caused by large expansions of a noncoding CGG repeat (>200 repeats) in the <i>FMR1</i> gene, at which point the gene is generally silenced. Absence of <i>FMR1</i> protein (FMRP), important for synaptic development and maintenance, gives rise to the neurodevelopmental disorder. There is, at present, no therapeutic approach that directly reverses the loss of FMRP; however, there is an increasing number of potential treatments that target the pathways dysregulated in FXS, including those that address the enhanced activity of the mGluR5 pathway and deficits in GABA pathways. Based on studies of targeted therapeutics to date, the prospects are good for one or more effective therapies for FXS in the near future.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39398874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. 钠-葡萄糖共转运蛋白2抑制剂在心力衰竭中的作用。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-13 DOI: 10.1146/annurev-pharmtox-052120-014725
Kevin S Shah, James C Fang
{"title":"Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.","authors":"Kevin S Shah,&nbsp;James C Fang","doi":"10.1146/annurev-pharmtox-052120-014725","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052120-014725","url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve blood glucose control by blocking renal glucose reabsorption with little subsequent risk of hypoglycemia. Consequently, there are decreases in plasma volume, body weight, and blood pressure. Additional putative benefits include improved cardiovascular energetics, decreased systemic inflammation, and less renal dysfunction. Multiple cardiovascular outcome trials in diabetic patients have demonstrated this drug class reduces the risk of adverse cardiovascular events. Reductions in heart failure (HF) hospitalization suggested that SGLT2 inhibitors might prove useful for the primary treatment of HF. Two large subsequent trials studying SGLT2 inhibitors in heart failure with reduced ejection fraction (HFrEF) demonstrated a reduction in cardiovascular mortality, HF hospitalizations, and renal-specific adverse events. This medication class is now recognized as a new pillar of therapy for patients with HFrEF. The cardiovascular and HF community await the results of ongoing trials of SGLT2 inhibition in patients with HF with preserved ejection fraction.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39414451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. HLA等位基因限制性免疫介导的药物不良反应:遗传预测框架。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-13 DOI: 10.1146/annurev-pharmtox-052120-014115
Kanoot Jaruthamsophon, Paul J Thomson, Chonlaphat Sukasem, Dean J Naisbitt, Munir Pirmohamed
{"title":"HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.","authors":"Kanoot Jaruthamsophon,&nbsp;Paul J Thomson,&nbsp;Chonlaphat Sukasem,&nbsp;Dean J Naisbitt,&nbsp;Munir Pirmohamed","doi":"10.1146/annurev-pharmtox-052120-014115","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052120-014115","url":null,"abstract":"<p><p>Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research studies have provided the evidence base to push forward the clinical implementation of HLA testing for the prevention of such ADRs in susceptible patients. This review explores current translational progress in using HLA as a key susceptibility factor for immune ADRs and highlights gaps in our knowledge. Furthermore, relevant findings of HLA-mediated drug-specific T cell activation are covered, focusing on cellular approaches to link genetic associations to drug-HLA binding as a complementary approach to understand disease pathogenesis.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39414452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Pushing Forward the Future Tense: Perspectives of a Scientist. 推进将来时:一个科学家的视角。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-08-02 DOI: 10.1146/annurev-pharmtox-052220-123748
Lee E Limbird
{"title":"Pushing Forward the Future Tense: Perspectives of a Scientist.","authors":"Lee E Limbird","doi":"10.1146/annurev-pharmtox-052220-123748","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052220-123748","url":null,"abstract":"<p><p>This review is a somewhat chronological tale of my scientific life, emphasizing the why of the questions we asked in the lab and lessons learned that may be of value to nascent scientists. The reader will come to realize that the flow of my life has been driven by a combined life of the mind and life of the soul, intertwining like the strands of DNA.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39268318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. 非p450药物代谢酶:对药物处置、毒性和发展的贡献。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-09 DOI: 10.1146/annurev-pharmtox-052220-105907
Tatsuki Fukami, Tsuyoshi Yokoi, Miki Nakajima
{"title":"Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development.","authors":"Tatsuki Fukami,&nbsp;Tsuyoshi Yokoi,&nbsp;Miki Nakajima","doi":"10.1146/annurev-pharmtox-052220-105907","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052220-105907","url":null,"abstract":"<p><p>Most clinically used drugs are metabolized in the body via oxidation, reduction, or hydrolysis reactions, which are considered phase I reactions. Cytochrome P450 (P450) enzymes, which primarily catalyze oxidation reactions, contribute to the metabolism of over 50% of clinically used drugs. In the last few decades, the function and regulation of P450s have been extensively studied, whereas the characterization of non-P450 phase I enzymes is still incomplete. Recent studies suggest that approximately 30% of drug metabolism is carried out by non-P450 enzymes. This review summarizes current knowledge of non-P450 phase I enzymes, focusing on their roles in controlling drug efficacy and adverse reactions as an important aspect of drug development.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39416210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Drug Target Identification in Tissues by Thermal Proteome Profiling. 热蛋白质组分析在组织中的药物靶标鉴定。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2022-01-06 Epub Date: 2021-09-09 DOI: 10.1146/annurev-pharmtox-052120-013205
André Mateus, Nils Kurzawa, Jessica Perrin, Giovanna Bergamini, Mikhail M Savitski
{"title":"Drug Target Identification in Tissues by Thermal Proteome Profiling.","authors":"André Mateus,&nbsp;Nils Kurzawa,&nbsp;Jessica Perrin,&nbsp;Giovanna Bergamini,&nbsp;Mikhail M Savitski","doi":"10.1146/annurev-pharmtox-052120-013205","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052120-013205","url":null,"abstract":"<p><p>Drug target deconvolution can accelerate the drug discovery process by identifying a drug's targets (facilitating medicinal chemistry efforts) and off-targets (anticipating toxicity effects or adverse drug reactions). Multiple mass spectrometry-based approaches have been developed for this purpose, but thermal proteome profiling (TPP) remains to date the only one that does not require compound modification and can be used to identify intracellular targets in living cells. TPP is based on the principle that the thermal stability of a protein can be affected by its interactions. Recent developments of this approach have expanded its applications beyond drugs and cell cultures to studying protein-drug interactions and biological phenomena in tissues. These developments open up the possibility of studying drug treatment or mechanisms of disease in a holistic fashion, which can result in the design of better drugs and lead to a better understanding of fundamental biology.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":null,"pages":null},"PeriodicalIF":12.5,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39398873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信